sulindac and Uremia

sulindac has been researched along with Uremia* in 2 studies

Trials

1 trial(s) available for sulindac and Uremia

ArticleYear
Reduced incidence of hyperkalemia and azotemia in patients receiving sulindac compared with indomethacin.
    Nephron, 1988, Volume: 48, Issue:4

    The incidence and severity of hyperkalemia and azotemia was investigated in a prospective randomized study involving 74 patients receiving either sulindac 200 mg p.o. b.i.d. or indomethacin 25 mg p.o. t.i.d. and 100 mg p.r. The mean +/- SE posttreatment increment in serum potassium was 0.8 +/- 0.1 mmol/l in patients treated by indomethacin compared to 0.5 +/- 0.1 in those receiving sulindac (p less than 0.025). The mean +/- SE posttreatment increment in blood urea nitrogen (BUN) was 3.1 +/- 0.4 mmol/l in patients on indomethacin compared to only 0.9 +/- 0.3 in patients on sulindac (p less than 0.001). In 5 patients who developed hyperkalemia while on indomethacin, changing to sulindac resulted in a sharp reduction of serum potassium in 3, and normalization of BUN in all patients. These data support the claim of a reduced risk of impaired renal function associated with the use of sulindac.

    Topics: Aged; Aged, 80 and over; Blood Urea Nitrogen; Female; Humans; Hyperkalemia; Indenes; Indomethacin; Male; Middle Aged; Potassium; Prospective Studies; Random Allocation; Sulindac; Uremia

1988

Other Studies

1 other study(ies) available for sulindac and Uremia

ArticleYear
Sulindac. A potentially renal-sparing nonsteroidal anti-inflammatory drug.
    JAMA, 1982, Dec-03, Volume: 248, Issue:21

    Three patients experienced rapidly reversible azotemia related to the use of naproxen or ibuprofen but tolerated full-dose sulindac. This article discusses renal toxicity of nonsteroidal anti-inflammatory drugs (NSAIDs), with emphasis on the role of inhibition of prostaglandin synthesis, and reviews evidence supporting a renal-sparing property of sulindac. The current literature assumes that all NSAIDs possess a similar potential for renal toxicity. The data presented suggest that sulindac has less potential for renal toxicity and may be the preferred NSAID for use in patients with impaired renal function.

    Topics: Aged; Anti-Inflammatory Agents; Arthritis; Female; Gout; Humans; Indenes; Kidney; Middle Aged; Sulindac; Uremia

1982